RxDoctor Payments Data

Misbah Zmily, MD

Internal Medicine · Raton, NMNPI 1285735332

Payments from drug & device makers

$561in general payments, 2019–2025

Across 31 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$121
  • Abbott$82
  • Boehringer Ingelheim$52
  • Xeris Pharmaceuticals, Inc.$45
  • Lilly USA, LLC$39
  • Amgen$34
  • plus $189 from 10 others

What the payments were for

  • Food & beverage$54697%
  • Education$153%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$561 in reported general payments places this provider in the 80th percentile of 578 internal medicine providers in New Mexico.

See all internal medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$805,159
Medicare patients
710
Services billed
12,966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide363$536,127
OzempicSemaglutide121$165,676
XareltoRivaroxaban48$52,793
EliquisApixaban34$38,885
AbrysvoRsv Vacc, Pref A And Pref B/Pf113$36,476
LinzessLinaclotide45$33,416
ZenpepLipase/Protease/Amylase14$31,991
Spiriva RespimatTiotropium Bromide26$25,569
ShingrixVaricella-Zoster Ge/As01b/Pf108$24,163
Stiolto RespimatTiotropium Br/Olodaterol Hcl36$22,349
FarxigaDapagliflozin Propanediol13$16,120
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$12,513
DuleraMometasone/Formoterol16$11,290
MyrbetriqMirabegron19$10,647
SymbicortBudesonide/Formoterol Fumarate27$8,896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$39$536,127363 claims
Johnson & JohnsonXarelto$21$52,79348 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$52$47,91862 claims
GSKShingrix, Trelegy Ellipta$16$36,676121 claims
AbbVieLinzess, Synthroid$21$35,647141 claims
AstraZenecaFarxiga, Symbicort$14$25,01740 claims
NovartisEntresto$121$7,99912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 578 internal medicine providers in New Mexico.

Other internal medicine in Raton

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →